Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 and ED95 of epidural ropivacaine with sufentanil for analgesia during HIFU treatment of adenomyosis
ChiCTR2400091541Phase 4Not yet recruiting
- Sponsor
- Suining Central Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ropivacaine in adenomyosis, sponsored by Suining Central Hospital. Primary endpoint: ED50 and ED95 of sufentanil + ropivacaine for intraoperative analgesia. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
adenomyosis
Beyond the preview
Go deeper on ChiCTR2400091541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091541.